Primary CNS Lymphoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Primary CNS Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions.
Primary CNS lymphoma (PCNSL) is a rare extranodal lymphoma that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without evidence of systemic involvement. It is a subtype on, and one of the most aggressive forms of, diffuse large B-cell lymphoma. PCNSL is more common in immunosuppressed patients, such as those with HIV/AIDS or transplant recipients, and is often associated with Epstein-Barr virus infection. PCNSL usually presents with neurological symptoms such as headache, seizure, cranial nerve deficits, or altered mental status, depending on the location and size of the tumor. The diagnosis of PCNSL requires histopathological confirmation from CSF cytology, vitreous biopsy, or brain/leptomeningeal biopsy. MRI or contrast-enhanced CT typically shows multiple ring-enhancing lesions in the deep white matter. The treatment of PCNSL consists of high-dose methotrexate-based chemotherapy, followed by consolidation with radiation, maintenance therapy, or stem cell transplant. The prognosis of PCNSL is poor, with a 5-year survival rate of 30-40%.
The Primary CNS Lymphoma drugs in development market research report provide comprehensive information on the therapeutics under development for Primary CNS Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary CNS Lymphoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Primary CNS Lymphoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 31 molecules, with 29 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Primary CNS Lymphoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Primary CNS Lymphoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Primary CNS Lymphoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAldeyra Therapeutics Inc
AstraZeneca Plc
Autolus Therapeutics Plc
BeiGene Ltd
Bristol-Myers Squibb Co
Celltrion Inc
Chengdu Hyperway Pharmaceutical Co Ltd
City of Hope
Curis Inc
Dayton Therapeutics AG
Eli Lilly and Co
Estrella Immunopharma Inc
Hangzhou Hezheng Pharmaceutical Co Ltd
InnoCare Pharma Ltd
Jiangsu Maidu Drug Research and Development Co Ltd
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Merck & Co Inc
MorphoSys AG
Novartis AG
Nurix Therapeutics Inc
Ono Pharmaceutical Co Ltd
Ossianix Inc
PentixaPharm GmbH
Systimmune Inc
University College London
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Primary CNS Lymphoma reports